Hyperthermie: Langjarige overleving door gecombineerde aanpak van chemo en lokale hyperthermie bij 58 patiënten met Ewing sarcoom en zes jaar studie follow-up.

31 oktober 2021: Zie ook dit artikel: https://kanker-actueel.nl/neoadjuvante-chemotherapie-plus-regionale-hyperthermie-bij-patienten-met-gelokaliseerd-hoogrisico-sarcoom-van-de-weke-delen-geeft-minder-recidieven-en-10-procent-betere-overall-overleving-na-5-en-10-jaar.html

december 2004: Bron: Pubmed: J Clin Oncol. 2002 Jul 15;20(14):3156-64. Langjarige overleving bij weke delentumoren - Sarcomen - door gecombineerde aanpak van chemokuren en lokale hyperthermie blijkt uit langjarige gerandomiseerde studie van 1991 tot 1997 bij 58 patiënten met ernstige vormen van weke delen kanker - sarcomen. In de groep van hyperthermie kwam veruit de langste levensduur voor. Deze studie is pas in 2002 gepubliceerd en onderaan staat dat een fase III studie is vereist voordat conclusies kunnen worden gemaakt. Zie ook recentere fase III studie uit 2010 ook uitgevoerd bij dr. Issels en is een vervolg op onderstaande studie

Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD. Department of Internal Medicine III, Diagnostic Radiology and Institute for Biostatistics and Epidemiology, Klinikum Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany. Clemens.Wendtner@med3.med.uni-muenchen.de

PURPOSE: To determine the efficacy of neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for local tumor control and overall survival (OS) in adult patients with retroperitoneal or visceral (RP/V) high-risk soft tissue sarcomas (HR-STS).

PATIENTS AND METHODS: From 1991 to 1997, 58 patients with HR-STS at RP/V sites were prospectively treated with four cycles of etoposide, ifosfamide, and doxorubicin combined with RHT followed by surgery, adjuvant chemotherapy, and radiation.

RESULTS: Objective response rate assessable in 40 patients was 13% (five partial responses). Including minor responses (n = 8), the radiographic response rate was 33%. The pathologic response rate assessable in 26 patients after surgical resection was 42%. Median OS was 31 months. At a median observation time of 74 months, 5-year probability of local failure-free survival (LFFS), distant metastasis-free survival, event-free survival, and OS were 25%, 51%, 20%, and 32%, respectively. Averaged minimum temperatures (T(min)) and time-averaged temperatures achieved in 50% (T(50)) and 90% (T(90)) of all measured tumor sites differed significantly between responders and nonresponders (T(min), 39.3 degrees C v 38.0 degrees C; P =.002; T(50), 40.9 degrees C v 40.3 degrees C; P =.038; T(90), 40.1 degrees C v 39.3 degrees C; P =.017). At 5-year follow-up, probability of LFFS (59% v 0%; P <.001) and OS (60% v 10%; P <.001) was significantly in favor of patients responding to neoadjuvant thermochemotherapy.

CONCLUSION: Response to neoadjuvant chemotherapy combined with RHT is predictive for an improved local tumor control resulting in a long-term survival benefit for patients with HR-STS at unfavorable RP/V sites; however, the impact of RHT has to be defined in a randomized phase III trial. PMID: 12118030 [PubMed - indexed for MEDLINE]

Ewing sarcoom, hyperthermie, chemo